Catalyst Pharmaceutical Partners (CPRX)

[hump4]

https://pressoracle.com/2018/10/28/catalyst-pharmaceuticals-inc-cprx-shares-bought-by-blackrock-inc.html

BlackRock Inc. grew its position in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 29.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,059,627 shares of the biopharmaceutical company’s stock after acquiring an additional 1,361,096 shares during the quarter. BlackRock Inc. owned about 5.91% of Catalyst Pharmaceuticals worth $18,905,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. GSA Capital Partners LLP raised its stake in shares of Catalyst Pharmaceuticals by 295.7% during the second quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock worth $1,187,000 after purchasing an additional 284,409 shares during the last quarter. Northern Trust Corp raised its stake in shares of Catalyst Pharmaceuticals by 22.5% during the first quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock worth $2,414,000 after purchasing an additional 185,639 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth approximately $476,000. Bank of New York Mellon Corp raised its stake in shares of Catalyst Pharmaceuticals by 15.7% during the second quarter. Bank of New York Mellon Corp now owns 274,813 shares of the biopharmaceutical company’s stock worth $858,000 after purchasing an additional 37,388 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Catalyst Pharmaceuticals by 24.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 184,904 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 36,200 shares during the last quarter. 51.49% of the stock is owned by institutional investors and hedge funds.